Efficacy and safety analyses of the TALENT trial (GETNE 1509): a phase II study of lenvatinib in patients (pts) with advanced G1/G2 pancreatic (panNETs) and gastrointestinal (ginets) neuroendocrine tumors
Authors
Capdevila, JBongiovanni, A
Hernando, J
Spada, F
Lopez, C
Teule, A
Merino, X
Lamarca, Angela
Tafuto, S
Custodio, A
Fazio, N
Ibrahim, T
Affiliation
Vall d'Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO) Barcelona, SpainIssue Date
2019